Targeted therapy for rare cancers
The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers
This study is testing whether a personalized cancer treatment based on specific gene changes can help people with rare and hard-to-treat cancers feel better and improve their outcomes.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 96 (estimated) |
| Ages | 16 Years to 99 Years |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Trial ID | NCT06119789 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with rare malignant neoplasms who may benefit from precision cancer therapy. It employs advanced molecular diagnostics to identify targetable alterations in tumor cells by analyzing over 500 genes at the DNA and RNA levels. Based on these molecular characteristics, patients will receive targeted treatments such as Imatinib, Trametinib, or Dabrafenib. The goal is to improve treatment outcomes for patients with hard-to-treat cancers.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with rare malignant neoplasms who have identified biomarkers and an ECOG performance status of 0-2.
Not a fit: Patients with serious other diseases or an ECOG performance status of 3-5 may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment options and outcomes for patients with rare cancers.
How similar studies have performed: Other studies have shown promise in using targeted therapies for specific molecular alterations in cancers, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ECOG 0-2, * identified biomarker, * reasonable biochemistry Exclusion Criteria: * ECOG 3-5 * serious other diseases
Where this trial is running
Oslo
- Oslo University Hospital — Oslo, Norway (Recruiting)
Study contacts
- Study coordinator: Åslaug Helland, MD PhD
- Email: ahelland@medisin.uio.no
- Phone: +4795940863
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.